COVID-19 and myocardial injury: Targeting elevated biomarkers for potential novel therapies.

Background: The prevalence of COVID-19 as the primary diagnosis among hospitalized patients with myocardial injury has increased during the pandemic and targeting elevated oxidant stress and inflammatory biomarkers may offer a potential role for novel therapies to improve outcomes.

Methods: At a single VA Medical Center from January 1 through December 31, 2021, troponin assays from patients being evaluated in the Emergency Room for consideration of admission were analyzed and peak levels from each patient were considered abnormal if exceeding the Upper Reference Limit (URL). Among admitted patients with an elevated troponin level, ICD-10 diagnoses were categorized, biomarker elevations were recorded, and independent predictors of death in patients with COVID-19 were determined at a median of 6-months following admission.

Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.

Background: Although beta-blockers are not recommended for the treatment of heart failure with preserved ejection fraction (HFpEF) according to the latest European Society of Cardiology and American Heart Association/American College of Cardiology/Heart Failure Society of America guidelines, these therapies remain commonly used for comorbidity management. There has been concern that beta-blockers may adversely influence clinical outcomes by limiting chronotropic response in HFpEF.

Objectives: This study sought to examine the contemporary use and implications of beta-blockers in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or HFpEF.

Drive Time and Receipt of Guideline-Recommended Screening, Diagnosis, and Treatment.

Importance: Many patients do not receive recommended services. Drive time to health care services may affect receipt of guideline-recommended care, but this has not been comprehensively studied.

Objective: To assess associations between drive time to care and receipt of guideline-recommended screening, diagnosis, and treatment interventions.

Drimane Sesquiterpene Aldehydes Control Yeast Isolated from Candidemia in Chilean Patients.

J.R. (Winteraceae) produce drimane sesquiterpenoids with activity against yeast.

COVID-19 postacute care major organ damage: a systematic review.

Background: Major organ complications have been reported in patients hospitalised for COVID-19; most studies lacked controls.

Objective: Examine major organ damage postdischarge among adults hospitalised for COVID-19 versus non-COVID-19 controls.

Data Sources: MEDLINE, Embase and Cochrane Library from 1 January 2020 to 19 May 2021.